STRATEC SE

Earnings Release • Nov 14, 2001

News Details

Ad-hoc | 14 November 2001 07:50

Stratec Biomedical Sys. english

Estimated Turnover For Entire Fiscal Year 2001 Clearly Surpassed After 9 Months Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– After nine months (Sept. 30, 2001) STRATEC has reached an accumulated turnover of 19 Mio. EUR, clearly exceeding the goal for the total fiscal year 2001. For the fiscal year 2001 STRATEC Biomedical Systems AG estimated a turnover of 16.4 Mio. EUR compared to the previous fiscal year’s turnover of 11.2 Mio. EUR (increase of 46 %). Compared with the same period of the preceding year, the earnings per share (EPS) have increased from (6) Cents* (minus six Cents) to 18 Cents* (*according to German commercial law). Key reasons for the outstanding improvement of the company figures are the widening of the customer base for the systems designed and manufactured by STRATEC and the very good market acceptance of our customer-specific solutions. The incoming orders and our customers’ forecasts, the finalization of development projects as well as the market launch of two versions of a STRATEC system platform in the coming periods promise further improvement of the company’s figures. end of ad-hoc-announcement (c)DGAP 14.11.2001 Issuer’s information/explanatory remarks concerning this ad-hoc-announcement: STRATEC Biomedical Systems AG (SIN 728 900) designs and manufactures fully automated systems for partners in clinical diagnostics and biotechnology. These partners sell the analysers to laboratories and research institutes worldwide as system solutions together with their reagents. STRATEC designs its products using its own patent-protected technologies. The fact that at this time last year the EBIT according to German commercial law was about minus 200 TEUR, whereas the EBIT of the overall year could be increased to over 600 TEUR according to German commercial law indicates the level of earnings produced in the last 3 months of the respective fiscal year in the past. These indicators justify hopes for a continued positive development. STRATEC Biomedical Systems AG is currently working on several major projects which will reach the phase of clinical testing and market launch in the periods to come. Negotiations with other major diagnostics and life-science companies promise – upon successful conclusion of an agreement and completion of the design process – further significant growth of the company. The 3rd quarter 2001 report will be available for download at http://www.stratec-biomedical.de form November 14, 2001 at 12 o’clock. In addition, it will be sent out via E-mail distribution list and via direct mail on this day. For further information, please contact us at +49 (0)7082 – 791633 or ir@stratec-biomedical.de. ——————————————————————————– WKN: 728900; Index: Listed: Geregelter Markt in Stuttgart; Freiverkehr in Berlin, Düsseldorf, Frankfurt und Hamburg 140750 Nov 01